

3rd March 2015

The Company Announcements Platform

ASX Limited

By E-lodgement

Prescient Therapeutics to Present at 27th Annual Roth Conference

Melbourne, Australia, 3rd March 2015: Prescient Therapeutics (ASX: PTX), a clinical stage oncology company, has been selected to present at the 27th Annual Roth Conference. This U.S. investor showcase is expected to attract around 3,000 attendees and will be held from March 9 - 12 in Dana Point, California.

Prescient's Managing Director, Dr Robert Crombie is scheduled to present the Company's investment case on Tuesday 10 March at 1.30 pm Pacific Daylight Time to delegates, including institutional and private equity investors, venture capitalists, and company executives. Dr Crombie's presentation will be available for review on the Company's website.

Roth Capital Partners is a leading global investment bank focused on the small-cap public market. Headquartered in Newport Beach, California, it also has offices in Boston, New York, Chicago, Larkspur, San Diego and Hong Kong.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's Lee Moffit Cancer Center. These trials are funded by grants from the U.S. Department of Defense and U.S. National Cancer Institute. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Further Inquiries:

Dr Robert Crombie

Managing Director

Ph: +61 (0) 439 361 331

Paul Hopper

Executive Director

US +1 858 334 5820

Rudi Michelson

Monsoon Communications

Ph: +61 (0) 3 9620 3333

Stephanie Carrington

Integrated Corporate Relations (ICR)

Ph: 646-277-1282

